Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
CADTH
Record ID 32014000846
English
Authors' recommendations:
The manufacturer's base result suggests that UA is cost-effective compared with LA in that it is both more effective and less costly. The CDR review identified certain weaknesses with assumptions made, and revised values for certain parameters were adopted in reanalysis. However, analysis reached the same conclusion as the manufacturer's submission in that UA was dominant over LA.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0326_Fibristal_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Leiomyoma
- Norpregnadienes
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.